A quick-release formulation of bromocriptine is the latest drug approved by the US Food and
Drug Administration for the treatment of type 2 diabetes mellitus. Most interestingly, the …

Objectives: To provide an evidence-based practice overview on the clinical use of
bromocriptine-quick release (QR) across the natural history of type 2 diabetes mellitus …

Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of
various hyperprolactinemic conditions and as adjunctive therapy for acromegaly (with or …

OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week …

198 and headache. Clinical trial data reveal that bromocriptine mesylate at doses up to 4.8
mg per day was not associated with a different rate of all-cause adverse events compared …

Bromocriptine, an ergot alkaloid derivative that possesses both dopamine agonist and
antagonist activity, has been studied in a broad spectrum of psychiatric illnesses. The …

The plasma kinetics of bromocriptine (BCT), a long-acting dopamine agonist, was studied in
twelve patients with Parkinson's disease, using a newly developed gas chromatographic …

In the treatment of hyperprolactinemia bromocriptine is generally administered in 3 daily
doses during the day. Due to the limited compliance of patients under this long term …

This paper reviews recent patents and development related to bromocriptine and other
dopaminergic agents, being used or suggested for use in the management of diabetes. The …

In this study we evaluated the effects of placebo or acute bromocriptine (BC) administration
(2.5 mg orally) on plasma catecholamines, systolic and diastolic blood pressure (BP), heart …